NanoViricides (NNVC) AI Stock Analysis

• Market Cap: $23.63M
• Dividend Yield: N/A
• Average Volume (3M): 248.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: 13.83%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.72
• Shares Outstanding: 16,072,000
• 10 Day Avg. Volume: 128,780
• 30 Day Avg. Volume: 248,019
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -87.66
• Enterprise Value/Ebitda: -1.81
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

NanoViricides' overall score is mainly impacted by its weak financial performance due to lack of revenue and ongoing losses. While technical analysis indicates some short-term positive momentum, the company's valuation remains a concern given its negative earnings. The absence of earnings call data and corporate events limits potential positive catalysts.

NanoViricides Business Overview & Revenue Model

Company Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

How the Company Makes Money

NanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.

NanoViricides Financial Statement Overview

Summary

NanoViricides is facing significant financial challenges characterized by lack of revenue, consistent operational losses, and cash burn. While the capital structure shows no debt, the reliance on equity and financing for operations underscores the urgency for revenue generation to ensure long-term viability.

Income Statement

NanoViricides has not generated any revenue in the TTM (Trailing-Twelve-Months) or previous years, leading to consistent negative gross and net profit margins. The company operates at a loss with EBIT and EBITDA margins also being negative, indicating ongoing financial challenges.

Balance Sheet

The company maintains a favorable debt position with zero total debt in the latest TTM, resulting in a strong equity ratio. However, the declining stockholders' equity and total assets over time suggest potential concerns regarding asset management and equity preservation.

Cash Flow

NanoViricides has negative operating and free cash flows, indicating cash burn without revenue generation. The company relies on financing activities to support operations, which may not be sustainable long-term without revenue growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-759.01K	-747.53K	-723.33K	-704.54K	-699.72K
EBITDA	-7.76M	-7.84M	-7.38M	-8.03M	-7.30M
Net Income	-8.29M	-8.59M	-8.10M	-8.91M	-13.40M
Balance Sheet
Total Assets	12.82M	16.90M	23.49M	30.26M	23.91M
Cash, Cash Equivalents and Short-Term Investments	4.80M	8.15M	14.07M	20.52M	13.71M
Total Debt	0.00	0.00	94.79K	95.31K	1.14M
Total Liabilities	1.36M	2.03M	412.84K	351.15K	2.16M
Stockholders Equity	11.46M	14.87M	23.08M	29.91M	21.76M
Cash Flow
Free Cash Flow	-6.47M	-5.82M	-6.22M	-8.45M	-6.67M
Operating Cash Flow	-6.32M	-5.67M	-5.89M	-8.21M	-6.67M
Investing Cash Flow	-156.56K	-151.71K	-324.35K	-238.76K	-8.64K
Financing Cash Flow	3.12M	-94.79K	-234.72K	15.26M	17.83M

NanoViricides Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Neutral. The current price of 1.5 is below the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.52, and above the 200-day MA of 1.38, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.72 is Neutral, neither overbought nor oversold. The STOCH value of 16.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NNVC.

NanoViricides Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.32B	5.55	-4.00%	3.32%	9.92%	-18.97%
OVID	54 Neutral	$59.75M	―	-52.77%	―	1071.91%	-27.61%
PULM	53 Neutral	$18.33M	―	-83.85%	―	-96.76%	26.87%
NNVC	42 Neutral	$23.63M	―	-99.84%	―	―	13.83%
CALC	39 Underperform	$36.47M	―	-209.36%	―	―	15.19%
ENLV	36 Underperform	$42.45M	―	-60.35%	―	―	53.82%
TENX	36 Underperform	$27.15M	―	-56.12%	―	―	95.87%